Gilead promotes Alessandro Riva to Senior VP, Hematology and Oncology Therapeutic Area Head
Gilead had revealed that it has promoted Dr Alessandro Riva, its Senior Vice President, Hematology and Oncology Therapeutic Area Head, to the position of Executive Vice President, Oncology Therapeutics. In his new role, he will hold responsibility for the company’s hematology and oncology programmes, including cell therapy research and development.
In his early career, Dr Riva served at Novartis as Head of Global Oncology Development where he held responsibility for the company’s range of tumour treatments from development through to regulatory approval. Joining Gilead in January 2017, he has been “instrumental” in the expansion of the firm’s oncology programme, especially in light of the recent Kite Pharma acquisition.
With this promotion, Dr Riva will also become a member of Gilead’s senior leadership team.
“Alessandro’s vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader haematology/oncology strategy,” commented John McHutchison, Executive Vice President of Clinical Research at Gilead. “In his new role, I am confident that Gilead’s haematology and oncology programs will continue to expand, as we seek to advance new therapies with the potential to transform the treatment of patients with cancer.”
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …
The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …